Core Viewpoint - Shanghai Shengsheng has submitted its listing application to the Hong Kong Stock Exchange, with CICC and Guojin Securities (Hong Kong) as joint sponsors. The company specializes in integrated temperature-controlled supply chain services for the pharmaceutical and life sciences industry, covering preclinical research, clinical trials, and post-market commercialization [1] Company Summary - Shanghai Shengsheng is the leading provider of temperature-controlled supply chain services in the pharmaceutical and life sciences sector in China, ranked first by revenue for 2024 according to Frost & Sullivan [1] - The company is the only Chinese enterprise among the top ten global providers of clinical trial temperature-controlled supply chain services, ranked ninth globally with a market share of 1.5% for 2024 [1] - The services offered by the company include project management, clinical packaging and labeling, temperature-controlled packaging, logistics and storage, drug recovery and destruction, bonded warehousing, import and export agency, customs clearance, direct delivery to patients, and biological sample management [1] - As of January 5, 2026, the company has served over 7,000 clients and operates clinical drug warehouses and biological sample banks in Shanghai, Beijing, and Guangzhou, with more than 130 operational sites providing efficient delivery services [1] Industry Summary - The global market for temperature-controlled supply chain services for commercial medical products is projected to grow from RMB 127.1 billion in 2020 to RMB 174.8 billion in 2024, with a compound annual growth rate (CAGR) of 8.3% [2] - The Chinese market is expected to grow from RMB 16.8 billion to RMB 22.9 billion during the same period, with projections to expand to RMB 38.6 billion by 2030 [2] - The share of cold chain categories in the commercial pharmaceuticals and medical products market in China continues to increase, driving demand for compliant cold chain distribution, professional storage, and integrated distribution services [2]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd.* 上海生生醫藥冷鏈科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、聯席全球協調人、顧問或包銷團成員表示 同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定；該文件的文本將於發售期內供公眾人士查閱。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資 ...